Exploration of Neuroimaging and Biochemical Prognostic Indicators for POCD
1 other identifier
observational
20
1 country
1
Brief Summary
Postoperative cognitive dysfunction (POCD) may lead to serious consequences. But the underlying mechanisms are still unclear. Blood Oxygen Level Dependent (BOLD) fMRI and biochemical indicators will be used to explore the underlying mechanisms and represent a promising precursory target for diagnosis and treatment of POCD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
June 12, 2014
CompletedFirst Posted
Study publicly available on registry
June 16, 2014
CompletedJune 16, 2014
May 1, 2013
1.1 years
June 12, 2014
June 13, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The brain structure changes
Using BOLD fMRI to investigate the variance of mean diffusivity and FA in nerve conduction bundle
7 days postoperatively
Secondary Outcomes (1)
Mini-Mental State Examination
preoperative and 7 days, 3 months and 1 years postoperative
Eligibility Criteria
Patients will selective undergo Coronary Artery Bypass Grafting (CABG) surgery. Health adult
You may qualify if:
- Aged 18-80 years old
- Underwent selective CABG surgery
You may not qualify if:
- History of central nervous system or psychiatric disorders
- History of taking sedative, antidepressants, or alcoholism
- MMSE score less than 23
- Visual or auditory disorders
- Educated less than 7 years
- Claustrophobia
- Can not be supine
- Can not tolerate iodinated contrast agents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- wangqianglead
Study Sites (1)
Xijign Hospital
Xi'an, Shaanxi, 710032, China
Biospecimen
4ml venous blood will be collected, and serum IL-6, IL-8,TNF-α,NSE,S100β will be detected.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Qiang Wang, MD, PhD
Xijing Hospital
- PRINCIPAL INVESTIGATOR
Zijun Gao, Dr.
Xijing Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 7 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 12, 2014
First Posted
June 16, 2014
Study Start
May 1, 2013
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
June 16, 2014
Record last verified: 2013-05